News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Akorn, Inc. (AKRN) Signs Letter Of Intent With Fidia Farmaceutici, S.p.A. To Develop Four ANDA Drug Products For Commercialization


10/19/2005 5:13:21 PM

BUFFALO GROVE, Ill.--(BUSINESS WIRE)--Oct. 13, 2005--Akorn, Inc. (AMEX:AKN) today announced that it has signed a Letter of Intent with Fidia Farmaceutici S.p.A., a privately-held pharmaceutical company located in Abano Terme (Padova), Italy, to develop four ANDA drug products. The Letter of Intent anticipates executing a Definitive Agreement within ninety days upon Terms and Conditions agreeable to both Akorn and Fidia.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES